Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.63 |
| ▸ | MMP9 | P14780 | 7/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436714 | 1.00 | MMP2 (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| Benzene SCHEMBL28198278 | 1.00 | MMP2 (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL698061 | 1.00 | MMP2 (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL27445164 | 0.94 | MMP2 (0.57) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| D-Phenylalanine SCHEMBL8609785 | 0.91 | ALPI (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL9012465 | 0.89 | MME (0.60) | MMP2MMP9ADAMTS4MME | |
| SCHEMBL16473194 | 0.88 | MMP2 (0.50) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL16886887 | 0.87 | CYP3A4 (0.57) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL16886884 | 0.87 | CYP3A4 (0.57) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL11471487 | 0.87 | POLB (0.49) | MMP2MMP9ADAMTS4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117337176-A | C5AR1 inhibitors for treating hypersensitivity to taxanes | 东佩制药股份公司 | 2024-01-02 | — | — | CN | claimed |
| CN-106947792-A | The preparation method of one inter-species methylsulfonyl L phenylalanines | 上海倍殊生物科技有限公司 | 2017-07-14 | — | — | CN | claimed |
| CN-117337176-A | C5AR1 inhibitors for treating hypersensitivity to taxanes | 东佩制药股份公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| CN-114174485-A | Cleaning agent and cleaning agent with improved enzyme stability | 汉高股份有限及两合公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3342599-B1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO LTD (JP) | 2021-06-16 | — | — | EP | disclosed |
| CN-108025574-B | Thermal recording medium | 三光株式会社 | 2019-04-16 | — | — | CN | disclosed |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| US-10086634-B2 | Heat-sensitive recording material | SANKO CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3342599-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Sanko Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-0301401-B1 | LEUKOTRIENE ANTAGONISTS, PROCESS FOR THEIR PREPARATION, THEIR USE IN THE TREATMENT OF ILLNESSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-27 | — | — | EP | disclosed |
| EP-0301402-B1 | LEUKOTRIENE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF ILLNESSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-21 | — | — | EP | disclosed |
| US-4855323-A | Leukotriene antagonists, a process for the preparation thereof, and the use thereof for the treatment of diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
| US-4851440-A | ASTHMA | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-07-25 | — | — | US | disclosed |
| EP-0157623-B1 | OPTICALLY ACTIVE ISOMERS OF BENZOPYRAN DERIVATIVES USEFUL FOR TREATING CARDIOVASCULAR DISEASE | KOWA COMPANY, LTD. (JP) | 1989-03-22 | — | — | EP | disclosed |
| EP-0301402-A1 | Leukotriene antagonists, process for their preparation and their use in the treatment of illnesses | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-01 | — | — | EP | disclosed |
| EP-0301401-A2 | Leukotriene antagonists, process for their preparation, their use in the treatment of illnesses | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-01 | — | — | EP | disclosed |
| US-4678803-A | CARDIOVASCULAR DISORDERS | KOWA COMPANY, LTD. (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0157623-A2 | Optically active isomers of benzopyran derivatives useful for treating cardiovascular disease | KOWA COMPANY, LTD. (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | ASIC1, SCN1A, NPR1 | MMP2 3267/4885MMP9 3602/4885ADAMTS4 4559/4885 |
| US-10086634-B2 | Heat-sensitive recording material | ASIC1, SCN1A, NPR1 | MMP2 3320/4885MMP9 3339/4885ADAMTS4 4570/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | MMP2 4186/4885MMP9 4685/4885ADAMTS4 3689/4885 |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | MMP2 3998/4885MMP9 4665/4885ADAMTS4 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.